SeraCare Life Sciences Inc. (NASDAQ: SRLS) shares are surging today after the Milford, Massachusetts-based company agreed to be acquired by private equity firm Linden Capital Partners.�
SeraCare Life Sciences shares rose to an intra-day high of $3.93, up 9.78% over the previous trading session. The stock is trading on above average volume of 5.80 million.�
SeraCare Life Sciences, which serves the global life sciences industry by providing products and services to facilitate the discovery, development and production of human and animal diagnostics and products, will be acquired �by an affiliate of Linden Capital Partners for $4 per share, under the terms of a definitive agreement.�
The offer price from Linden, which focuses on healthcare and life sciences sector, represents a premium of 12% over SeraCare shares closing price on Friday. The transaction has been approved by the SeraCare Board.�
Greg Gould, Interim President and CEO and CFO of SeraCare, Life Sciences, said that the company�s commitment to providing vital products and services of the highest quality has driven its growth and diversification across a blue chop life sciences customer base. Gould said that Linden is a natural strategic fit for SRLS, with a proven record of operating successful companies in the healthcare and life sciences sector. He added that Linden�s acquisition of SeraCare recognizes the company�s accomplishments and translates them into significant value for shareholders.�
Fran Lunger, Operating Partner at Linden, said that SRLS� product offerings, services and strong customer base provide an attractive foundation on which to compete and grow in the global high-growth markets of human diagnostics and therapeutics research and development.�
No comments:
Post a Comment